Udenafil: efficacy and tolerability in the management of erectile dysfunction
- 14 December 2012
- journal article
- Published by SAGE Publications in Therapeutic Advances in Urology
- Vol. 5 (2), 101-110
- https://doi.org/10.1177/1756287212470019
Abstract
Udenafil is a potent novel phosphodiesterase-5 inhibitor approved for use in Korea. Udenafil has unique properties, with a Tmax of 1.0–1.5 h and a T1/2 of 11–13 h (a relatively rapid onset and a long duration of action). Therefore, both on-demand and once-daily use of udenafil have been reported. Udenafil’s efficacy and tolerability have been evaluated in several studies, and recent and continuing studies have demonstrated udenafil’s promise in both dosing regimens. Presently, tadalafil is the only FDA-approved drug for daily dosing, but udenafil can be used as a once-daily dose for erectile dysfunction patients who cannot tolerate tadalafil due to phosphodiesterase subtype selectivity. Udenafil as an on-demand or once-daily dose is effective and tolerable, but more studies are needed in patients of other ethnicities and with comorbid conditions such as diabetes mellitus, hypertension, and benign prostate hyperplasia.Keywords
This publication has 35 references indexed in Scilit:
- Anterior Ischemic Optic Neuropathy Associated with UdenafilKorean Journal of Ophthalmology, 2012
- Efficacy and Safety of Once-Daily Dosing of Udenafil in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialEuropean Urology, 2011
- A Therapeutic Confirmatory Study to Assess the Safety and Efficacy of Zydena® (Udenafil) for the Treatment of Erectile Dysfunction in Male Patients with Diabetes MellitusThe Journal of Sexual Medicine, 2011
- Efficacy of Udenafil for the Treatment of Erectile Dysfunction up to 12 Hours after Dosing: A Randomized Placebo-Controlled TrialThe Journal of Sexual Medicine, 2010
- Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature EjaculationEuropean Urology, 2010
- A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibitionBJU International, 2010
- Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjectsBritish Journal of Clinical Pharmacology, 2008
- Lower urinary tract symptoms and sexual dysfunction: a common approachBJU International, 2008
- HYPERTENSION IS ASSOCIATED WITH SEVERE ERECTILE DYSFUNCTIONJournal of Urology, 2000
- Erectile DysfunctionThe New England Journal of Medicine, 2000